Rate My Professor Emanuel Petricoin

Emanuel F. Petricoin III is a University Professor in the School of Systems Biology within the Biology faculty at George Mason University and Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) since 2005. He earned his Ph.D. in Microbiology from the University of Maryland, College Park, in 1990. Prior to joining George Mason University, Dr. Petricoin served as Co-Director of the FDA-NCI Clinical Proteomics Program and as a Senior Investigator in the Center for Biologics Evaluation and Research at the Food and Drug Administration from 1993 to 2005. His research centers on the invention and application of proteomics technologies for personalized therapy, biomarker discovery, and measurement with direct clinical applications at the bedside. The CAPMM, co-directed by Dr. Petricoin and Lance Liotta, focuses on translational research in diseases such as various cancers, Alzheimer’s disease, traumatic brain injury, cardiovascular disease, liver and obesity disorders, and infectious diseases including sepsis and Lyme disease. Since its founding in 2005, the center has produced 132 publications and 44 patent applications in these areas.

Dr. Petricoin is a co-founder of four life science companies: Theranostics Health, Inc., Ceres Nanosciences Inc., C-4 Diagnostics, Inc., and Perthera, Inc. He is a co-inventor on 40 filed and published patents and has authored over 350 peer-reviewed publications, over 40 invited reviews, and 40 book chapters. He serves on the editorial boards of Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular Carcinogenesis, and Journal of Personalized Medicine, and is a Senior Editor for Cancer Epidemiology, Biomarkers and Prevention. A founding member of the Human Proteome Organization (HUPO) and US HUPO, he served on HUPO’s Executive Committee and as Treasurer from 2002 to 2004. He is the faculty representative to the George Mason University Research Foundation and represents the university on the Board of Directors for the Virginia Health Research Biosciences Corporation. His distinguished contributions have earned him the University Professorship at George Mason University, NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs recognition, Nifty 50 Award, American Society of Cytopathology Basic Research Award, Roche Diagnostics/CLAS Distinguished Scientist Award, and Harvard University Leading Edge Award. Recently, he received funding for projects including protein pathway activation mapping of head and neck cancers.